文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-DOTA-FAPI-04 PET/CT对前列腺癌成像的贡献:在PSMA阴性病例中的补充作用

Contribution of 68 Ga-DOTA-FAPI-04 PET/CT to Prostate Cancer Imaging : Complementary Role in PSMA-Negative Cases.
PubMed 文献 · Clin Nucl Med · 2024-01-25

纳入36例前列腺癌患者,均在一周内接受68Ga-PSMA PET/CT与68Ga-DOTA-FAPI-04 PET/CT。分期组中FAPI-04阳性率高于PSMA(74%对52%),PSMA阴性患者中FAPI-04阳性率达54%;生化复发组所有病灶PSMA摄取均高于FAPI-04。

要点

  • 分期组27例中FAPI-04阳性20例(74%),PSMA阳性14例(52%)。
  • PSMA阴性患者中FAPI-04阳性率为54%。
  • 生化复发组5处病灶PSMA摄取均高于FAPI-04。

核心结论

  • FAPI PET在前列腺癌成像中对PSMA PET有补充潜力,超过半数PSMA阴性病例呈FAPI阳性。
  • FAPI靶向放射性核素治疗对PSMA靶向治疗耐药患者可能是一种有前景的方法。

研究设计与样本

  • 纳入36例确诊前列腺癌患者。
  • 患者均在1周内接受68Ga-PSMA PET/CT和68Ga-DOTA-FAPI-04 PET/CT。
  • 分期组比较原发肿瘤摄取,并与组织病理、MRI及总PSA水平进行相关性分析。
  • 生化复发组评估前列腺区域及转移灶摄取以判定局部复发或转移。

主要发现

  • 分期组PSMA PET原发灶摄取增高14/27例(52%),FAPI-04 PET阳性20/27例(74%)。
  • PSMA阴性患者中FAPI-04阳性率为54%。
  • ISUP 1-3级与ISUP 4-5级患者间FAPI-04 PET差异有统计学意义(P=0.03)。
  • 生化复发组检出局部复发3例、盆腔淋巴结转移1例、骶骨转移1例,所有病灶PSMA摄取均较FAPI-04更浓。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate-specific membrane antigen (PSMA)-targeted PET/CT is a well-established imaging method in prostate cancer (PC) for both staging and restaging, and also for theranostic applications. An alternative imaging method is crucial for 15% PSMA-negative cases. We aimed to investigate the contribution of 68 Ga-DOTA-FAPI-04 PET/CT to PC imaging. PATIENTS AND METHODS: Thirty-six patients diagnosed with PC were included. Patients underwent both 68 Ga-PSMA PET/CT and 68 Ga-DOTA-FAPI-04 PET/CT imaging within 1 week. In staging group, primary tumor uptake values were compared, and also correlations were done with histopathological findings, MRI findings, and total PSA levels. In biochemical recurrence group, the uptake values in prostatic region and metastases were evaluated to define the local recurrence or metastatic disease. RESULTS: In staging group, PSMA PET showed increased uptake in the primary lesion area in 14/27 (52%) patients, whereas 20/27 (74%) patients were positive in FAPI-04 PET. FAPI-04 positivity was found to be quite high, such as 54%, in PSMA-negative patients. A significant difference was observed between ISUP grade 1-3 patients and ISUP grade 4-5 patients in FAPI-04 PET ( P = 0.03). Local recurrence was detected in 3 patients, pelvic lymph node metastasis in 1 patient, and sacrum metastasis in 1 patient in biochemical recurrence group, and all of the lesions had more intense uptake in PSMA PET than FAPI-04 PET. CONCLUSIONS: FAPI PET imaging seems to have a potential to contribute PSMA PET imaging with FAPI positivity in more than half of PSMA-negative cases. Also, FAPI-targeted radionuclide therapy may be a promising method in patients resistant to PSMA-targeted therapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ergül N, Çermik TF, Alçın G, et al. Contribution of 68 Ga-DOTA-FAPI-04 PET/CT to Prostate Cancer Imaging : Complementary Role in PSMA-Negative Cases. Clin Nucl Med. 2024. PMID: 38271254. doi:10.1097/RLU.0000000000005064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。